AAV Expression Construct Modular Design for Stable Insect Cell Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved systems and methods for producing adeno-associated virus (AAV) structural and nonstructural proteins and corresponding vectors, particularly for enhanced production stability, viral titers, capsid quality, and transduction efficiency.
Innovation Solution
The development of AAV expression constructs comprising specific Rep-coding regions and VP-coding regions, integrated into a variant baculovirus genome with disruptions of non-essential genes, allowing for stable maintenance and expression of AAV capsid proteins and replication proteins in insect cells, such as Sf9 or Sf21 cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional AAV expression constructs are used, then production process is simple, but passage stability is poor and viral titers are low
Solution Approach 1:
The expression construct is divided into separate functional modules: Rep-coding regions for replication proteins, VP-coding regions for capsid proteins, and specific promoter elements (polh promoter for Rep proteins, p10 promoter for VP proteins). This segmentation allows independent optimization of each component's expression control, achieving stable maintenance through modular design while maintaining manageable complexity.
Solution Approach 2:
The patent modifies key parameters of the expression construct including: using specific promoters (polh, p10) to control expression timing and levels, incorporating modified Kozak sequences to enhance translation efficiency, and optimizing codon usage for insect cells. These parameter changes result in improved passage stability and viral titers without excessive complexity.
2Manufacturing precision
If conventional AAV expression constructs are used, then manufacturing process is simple, but capsid protein ratios are poor and capsid quality is low
Solution Approach 1:
Different promoters are assigned to different functional regions: the polh promoter specifically drives Rep protein expression while the p10 promoter drives VP protein expression. This local quality assignment ensures appropriate expression levels and timing for each protein type, achieving precise capsid protein ratios (VP1:VP2:VP3) and high capsid quality through localized expression control.
Solution Approach 2:
The expression construct is designed with pre-optimized elements including modified Kozak sequences at the VP-coding region to enhance translation initiation, and predetermined promoter placements that activate specific proteins at appropriate stages. This preliminary optimization ensures high capsid protein ratios and quality from the outset, simplifying the actual production process.
3Productivity
If conventional AAV expression constructs are used, then production system is simple, but viral titers are low and transduction efficiency is poor
Solution Approach 1:
The expression construct is designed to perform multiple functions simultaneously: Rep-coding regions produce replication proteins for viral assembly, VP-coding regions produce capsid proteins for particle formation, and the integrated promoters ensure coordinated expression. This multi-functionality within a single construct achieves high viral titers and transduction efficiency without proportionally increasing system complexity.
Solution Approach 2:
The patent uses specific intermediary elements including the polh promoter as a mediator for Rep protein expression and the p10 promoter as a mediator for VP protein expression. These promoter intermediaries coordinate the timing and levels of different protein expressions, enabling high viral titers and efficient transduction while maintaining a manageable production system complexity.
Data Source
AI summary
The present disclosure describes methods and systems for use in the production of adeno-associated virus (AAV) particles, including recombinant adeno-associated virus (rAAV) particles. In certain embodiments, the production process and system use Spodoptera frugiperda insect cells (such as Sf9 or Sf21) as viral production cells (VPCs).